We are live on ! Find out more
KCM

Kennedy Capital Management Portfolio holdings

AUM $4.72B
1-Year Est. Return 36.69%
This Fund
S&P 500
This Quarter Est. Return
+9.83%
1 Year Est. Return
+36.69%
3 Year Est. Return
+98.85%
5 Year Est. Return
+128.89%
10 Year Est. Return
+548.51%
AUM
$4.19B
AUM Growth
+$8.49M
Cap. Flow
-$236M
Cap. Flow %
-5.63%
Top 10 Hldgs %
9.13%
Holding
691
New
49
Increased
226
Reduced
294
Closed
110

Top Buys

Rank Stock Value
1
G icon
Genpact
G
+$15.7M
2
SN icon
SharkNinja
SN
+$10.3M
3
COLD icon
Americold
COLD
+$8.79M
4
MRCY icon
Mercury Systems
MRCY
+$8.73M
5
OSBC icon
Old Second Bancorp
OSBC
+$7.85M

Sector Composition

Rank Sector Weight
1 Financials 20.3%
2 Industrials 19.06%
3 Healthcare 16.19%
4 Technology 14.12%
5 Consumer Discretionary 8.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NTRA icon
551
Natera
NTRA
$45.9B
$282K 0.01%
1,668
-1,756
-51% -$274K
MX icon
552
Magnachip Semiconductor
MX
$134M
$257K 0.01%
64,592
-29,800
-32% -$104K
NAMS icon
553
NewAmsterdam Pharma
NAMS
$3.34B
$248K 0.01%
+13,675
New +$249K
FHN icon
554
First Horizon
FHN
$12B
$237K 0.01%
11,194
-64,164
-85% -$1.22M
AMD icon
555
Advanced Micro Devices
AMD
$767B
$233K 0.01%
+1,640
New +$179K
MGTX icon
556
MeiraGTx Holdings
MGTX
$1.21B
$229K 0.01%
35,189
+1,287
+4% +$7.6K
EME icon
557
Emcor
EME
$35.7B
$226K 0.01%
+422
New +$186K
WVE icon
558
Wave Life Sciences
WVE
$1.2B
$221K 0.01%
+34,000
New +$225K
CYTK icon
559
Cytokinetics
CYTK
$10.5B
$220K 0.01%
6,671
+165
+3% +$5.74K
JANX icon
560
Janux Therapeutics
JANX
$1B
$220K 0.01%
9,508
-7,093
-43% -$187K
PCVX icon
561
Vaxcyte
PCVX
$8.67B
$217K 0.01%
6,671
+165
+3% +$5.41K
KYMR icon
562
Kymera Therapeutics
KYMR
$9.03B
$211K 0.01%
+4,836
New +$167K
XEL icon
563
Xcel Energy
XEL
$48B
$209K 0.01%
3,074
FERG icon
564
Ferguson
FERG
$51.2B
$207K ﹤0.01%
+952
New +$175K
VOE icon
565
Vanguard Morningstar Mid-Cap Value ETF
VOE
$24.2B
$207K ﹤0.01%
+1,260
New +$200K
SNA icon
566
Snap-on
SNA
$21.3B
$206K ﹤0.01%
661
EMR icon
567
Emerson Electric
EMR
$88.5B
$205K ﹤0.01%
+1,539
New +$177K
VLO icon
568
Valero Energy
VLO
$90.7B
$201K ﹤0.01%
+1,493
New +$186K
BDTX icon
569
Black Diamond Therapeutics
BDTX
$114M
$163K ﹤0.01%
65,875
+2,352
+4% +$4.53K
TRVI icon
570
Trevi Therapeutics
TRVI
$2.54B
$152K ﹤0.01%
27,851
+595
+2% +$3.7K
ARCT icon
571
Arcturus Therapeutics
ARCT
$200M
$152K ﹤0.01%
11,674
+544
+5% +$6.43K
MITK icon
572
Mitek Systems
MITK
$837M
$144K ﹤0.01%
+14,532
New +$131K
RAPP
573
Rapport Therapeutics
RAPP
$2.25B
$128K ﹤0.01%
+11,230
New +$119K
NTLA icon
574
Intellia Therapeutics
NTLA
$1.68B
$127K ﹤0.01%
13,509
+496
+4% +$4.07K
ATYR
575
aTyr Pharma
ATYR
$51.9M
$109K ﹤0.01%
+21,514
New +$84.6K

Similar funds

Kennedy Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Kennedy Capital Management held 691 positions worth $4.19B, up 0.2% from $4.19B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.

Kennedy Capital Management withdrew a net $236M in Q2 2025, closing 110 positions and reducing 294 holdings. Its most notable exit was Columbia Banking Systems, an estimated $14.4M position sold in full.

By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 21% a quarter earlier, followed by Industrials and Healthcare.

Against the trend, Kennedy Capital Management opened a new position in Genpact worth $15.3M.

  • Kennedy Capital Management's largest Q2 2025 buy was Genpact: 347,353 shares worth $15.3M.
  • Kennedy Capital Management added most to Mercury Systems in Q2 2025, an estimated $8.73M increase.
  • Kennedy Capital Management's biggest Q2 2025 reduction was Hexcel, cutting an estimated $21.3M.
  • Kennedy Capital Management fully exited Columbia Banking Systems in Q2 2025, selling an estimated $14.4M.
  • Kennedy Capital Management's ten largest holdings make up 9.1% of its $4.19B portfolio in Q2 2025.
  • Kennedy Capital Management opened 49 new positions and closed 110 in Q2 2025.
  • Kennedy Capital Management's portfolio value rose 0.2% quarter-over-quarter to $4.19B.

Based on Kennedy Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.